Request demo
  • About Cresset

Your trusted molecular computational chemistry partner

Our proven experience delivers value for your R&D team
REQUEST EVALUATION, DEMO OR DISCUSSION

Over decades of working with discovery R&D teams, Cresset has built up vast experience of applying simulation to speed the process from target validation to candidate selection. But it’s not just what we can do – it’s how we do it. Customers tell us that they appreciate how we listen, collaborate, and focus on delivering value. We’re committed to this trusted partner model, working together to achieve discovery success.

Focus on customer success

Our key values include putting customers first – listening, collaborating, and delivering great value – and a focus on outcomes – finding solutions to critical discovery challenges with outstanding usability. These values drive everything about how we organise ourselves. Every commercial customer has a dedicated account manager and access to our Solutions scientists who can advise them on the best way to maximize their use of Cresset technology. Our dedicated training team can get you up-to-speed quickly. Our customer support team respond quickly to questions and support issues. Our Discovery Services are available to any customer seeking more assistance with accelerating their R&D.

Solutions driven by you

When we asked customers what they like about the Cresset approach, they told us that we listen carefully with an open mind, respond to their ideas and requirements, and apply our expertise effectively to help them. We’re investing resources and effort to maintain and build on this reputation. We work collaboratively with customers, sharing future roadmaps and often integrating ideas from customers into our development program. We encourage feedback and sharing of experience through user groups. And we value the individual scientific relationships that our team builds with customers, partners, and other collaborators.

Outstanding molecular discovery expertise

Underpinning our partnership with customers is the vast molecular discovery experience built up over 20+ years and embodied in our scientific team. With 500+ projects completed, 50+ papers published, and an on-going commitment to innovation, this team works with you day-to-day through our support and Discovery Services functions.

Our Scientific Advisory Board helps us to maintain our focus on innovation and to nurture our scientific talent. You can access and apply this unrivalled knowledge source, while retaining full, secure ownership over any IP relating to your projects as we collaborate.

We’re making it our mission to be the model for how computational chemistry companies should work with the industry – your preferred partner.
Tim Cheeseright
CEO

Learn how we're putting partnership first

Read blog

Secure provider

We’re committed to providing the highest levels of customer data security and integrity, demonstrated by our SOC 2® Type 1 compliance and Cyber Essentials certification.

Learn more about our commitment to security and compliance and why we’re trusted by the world’s leading pharma and biotech organizations.

What our customers say

“As a global computational chemistry team within a contract research organisation (CRO), we aimed to improve the consistency, scalability, and scientific rigor of our molecular modelling workflows across a wide range of client projects. Cresset supported a smooth transition from a previously used commercial tool and helped address key limitations around accessibility and deployment at scale. A differentiated licensing model has enabled broad access across chemistry and biology teams while reserving advanced capabilities for computational chemistry specialists. This approach has helped balance accessibility, scientific depth, and efficient use of resources, enabling wider engagement without compromising rigor. The Cresset team have been highly responsive and knowledgeable, working closely with us to support adoption across a global user base. Training was organised according to user needs, with regular office hours providing an open forum for questions and ongoing support.

Overall, Cresset has become a valuable part of our computational chemistry toolkit, strengthening consistency, productivity, and confidence in decision-making across our organisation.”

Nicola Porta, Senior Scientist, Evotec

We are pleased to be working with Cresset’s software. This provides us with intuitive molecule design, a powerful ability to understand SAR and design plus a fresh way for generating novel and diverse structures for our projects.

Dr Kristian Birchall, Medical Research Council Technology, UK

We really like the powerful combination of excellent software tools and molecular design expertise which we get from working with Cresset.

Dr Graham Sibley, Head of Chemistry, F2G, UK

We wanted to use computational methods to suggest alternative substructures which could replace part of one of our key leads. We’d looked at other tools previously, without success, then turned to the Spark™ field-based approach. We looked at the top 50 hits from Spark and selected a subset to synthesise. Whilst the synthesised compounds exhibited a broad range of activities, we were delighted to observe that a number turned out to be nanomolar hits – with several even more potent than the original lead. One of these compounds is now our key lead against this target and further analogue synthesis is underway. Spark has certainly helped direct us towards some novel and very useful SAR on this occasion.

Laurent Rigoreau, Group Leader Medicinal Chemistry, Cancer Research Technology Discovery Laboratories

Cresset Discovery’s computational experience and high standard of scientific support is ideally suited to help drive the next stage of this project.

Dr Richard Boyce, Senior Director of Research, PhoreMost

The protein interaction potential capability [in Flare] highlighted common features across the family of targets of interest that we had not been able to visualize before. We used this information to drive ligand design into a direction we have not explored before.

Dr Martin Quibell, MAQU Chemistry Consulting, UK

We sought the scientific expertise within the Cresset Discovery team to utilize their novel field and shape-based virtual screening methods in Blaze™, and their proprietary Electrostatic Complementarity™ technique to help identify a backup series for our target effectively and efficiently. Ultimately we identified 9 novel chemotypes that were clearly distinct to those arising from docking and pharmacophore virtual screening approaches, which was an exciting outcome for us.

Dr Zara Sands, Head of CADD and Informatics, Confo Therapeutics, Belgium

Working closely with the Cresset Discovery team we aimed to identify a putative binding pose for a lead series in published PDB coordinates that was not only consistent with the kinetically deduced MOA but explained the established SAR as well. The furnished results were able to satisfy these goals and then be applied prophetically for ligand design purposes.

Twentyeight-Seven Therapeutics, USA

Medicinal chemists in my team find the covalent docking feature in Flare™ very intuitive to use.

Matthias Bauer, AstraZeneca, UK